Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
DBV Technologies reported its second quarter 2021 financial results on August 2, 2021, highlighting progress in the development of its Viaskin Peanut patch. The company submitted a protocol for a critical study to the FDA and completed an adhesion trial, selecting two superior patch designs. Cash and cash equivalents stood at $125.5 million, down from $196.4 million at year-end 2020, expected to support operations until mid-2022. DBV's net loss narrowed to $30.7 million for Q2 2021, down from $48.2 million the previous year, with significant reductions in operating expenses attributed to budget discipline measures.
DBV Technologies, a clinical-stage biopharmaceutical company, will report its first half 2021 financial results and business updates on August 2, 2021. A conference call and live audio webcast will take place at 5:00 p.m. ET. Viaskin™, the company's investigational platform for immunotherapy, aims to transform the care of food allergic patients, with ongoing trials for Viaskin Peanut. The presentation will be available on their website, along with a replay post-event.
As of June 30, 2021, the total number of shares for the company was 55,011,687. This included 54,933,812 voting rights after accounting for shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is crucial for investors monitoring voting power and company governance. The data is available on the NYSE Euronext Paris market under the ISIN Code: FR 0010417345.
As of May 31, 2021, the company reported a total of 55,011,687 shares outstanding. The total gross voting rights are also at 55,011,687, while the net voting rights stand at 54,943,413. This announcement complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that CEO Daniel Tassé will participate in two upcoming virtual investor conferences in June 2021. The first is at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 8:50am ET, followed by the JMP Life Sciences Conference on June 16, 2021, at 10:00am ET. A live webcast of these events will be available on the company's website, where replays will also be accessible later. DBV is focused on developing Viaskin™, a technology aimed at immunotherapy for food allergies.
DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting on May 19, 2021, where shareholders approved all proposed resolutions. Notably, Dr. Adora Ndu and Dr. Ravi Madduri Rao were appointed as independent board members, while Dr. Torbjorn Bjerke retired. The board now consists of ten directors. Dr. Ndu and Dr. Rao bring extensive experience in drug development and regulatory affairs, aiming to support the strategic objectives of DBV, particularly in the advancement of Viaskin Peanut.
As of April 30, 2021, the company reported a total of 54,936,687 shares outstanding. The total number of voting rights amounted to 54,936,687 gross and 54,887,687 net after excluding non-voting shares. This information is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The data reflects important metrics regarding shareholder influence and governance.
DBV Technologies has filed its first Form 10-Q for Q1 2021 with the U.S. SEC. This document is available on both the company's website and the SEC’s website. DBV Technologies is focused on developing Viaskin™, a non-invasive immunotherapy platform aimed at treating food allergies, including ongoing trials for Viaskin Peanut. The company operates globally with headquarters in France and North American operations in New Jersey, and its stock is traded on Euronext Paris and Nasdaq (ticker: DBVT).
DBV Technologies reported its Q1 2021 financial results, showing a cash balance of $152.5 million as of March 31, down from $196.4 million at year-end 2020. The net loss narrowed to $(29.4 million), or $(0.54) per share, compared to $(40.9 million) and $(0.79) per share in Q1 2020. Operating income fell 37.7% to $2.9 million, primarily due to reduced research tax credits. Operating expenses decreased 29.2% to $32.6 million, attributed to workforce reductions. DBV expects current cash reserves to fund operations until mid-2022.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical firm, announced participation in two virtual investor conferences in May 2021. Dr. Pharis Mohideen and CFO Sebastien Robitaille will represent the company at the Kempen Life Sciences Conference on May 5, while CEO Daniel Tassé and Robitaille will attend the Societe Generale Nice Conference on May 27. DBV is focused on developing Viaskin™, a novel technology platform for immunotherapy aimed at treating food allergies through epicutaneous delivery.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
